The feasibility of generating an active, CTA-specific immune response in vitro indicates the expression of the CTAs Sp17, AKAP-4 and PTTG1 by NSCLC cells could have therapeutic relevance and serve as the basis for designing novel immunotherapeutic strategies against this disease. This evidence concerns the gene AKAP4 and non-small cell lung carcinoma.